One such promising therapy [3], which has recently been approved as a standard treatment option for CLL and small lymphocytic lymphoma, is venetoclax (ABT-199), which is a Bcl-2-specific protein inhibitor. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.